Active Biotech’s business strategy is to develop proprietary products through partnerships.
Current collaborations include partnerships with NeoTX Therapeutics Ltd. for development of naptumomab estafenatox in cancer. An academic partnership to advance tasquinimod for treatment of multiple myeloma has recently been established.
NeoTX Therapeutics Ltd.
On October 26, 2016 – Active Biotech announced an agreement with NeoTX Therapeutics Ltd., for the development and commercialization of naptumomab estafenatox for cancer immunotherapy.
The licensing agreement grants NeoTX exclusive rights to develop and commercialize naptumomab estafenatox worldwide in cancer indications. The total deal value amounts to USD 71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech received USD 250,000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.